Rasmussen C, Bergh T, Wide L, Brownell J
Department of Obstetrics and Gynaecology, Uppsala University, Sweden.
Clin Endocrinol (Oxf). 1988 Sep;29(3):271-9. doi: 10.1111/j.1365-2265.1988.tb01225.x.
Twenty-four hyperprolactinaemic women were treated for 6 months with the new, non-ergot, long-acting dopamine agonist, CV 205-502. The treatment resulted in normalization of PRL secretion in 17 of the 24 women at once-daily doses of 0.05 to 0.15 mg of the drug. Sixteen of these women as well as 4 of those who remained hyperprolactinaemic had regular menstrual bleeding. Five of the patients had previously discontinued bromocriptine therapy because of adverse effects but had no problems tolerating CV 205-502. Of three bromocriptine-resistant women, two responded partially while one also remained unresponsive to CV 205-502 treatment. Mild to moderate galactorrhoea was recorded at baseline in 19 of the 24 women. After 6 months' treatment mild galactorrhoea was still present in six patients, four of whom had attained normal PRL levels. Side-effects were mild and transient. CV 205-502 seems to be a valuable compound in the management of patients with hyperprolactinaemia.
24名高泌乳素血症女性接受了新型非麦角长效多巴胺激动剂CV 205 - 502治疗6个月。在每日服用0.05至0.15毫克该药物的情况下，24名女性中有17名的泌乳素（PRL）分泌恢复正常。这些女性中有16名以及4名仍为高泌乳素血症的女性出现了规律的月经出血。5名患者之前因不良反应停用了溴隐亭治疗，但在服用CV 205 - 502时未出现耐受问题。在3名对溴隐亭耐药的女性中，2名有部分反应，1名对CV 205 - 502治疗仍无反应。24名女性中有19名在基线时记录有轻至中度溢乳。治疗6个月后，6名患者仍有轻度溢乳，其中4名患者的PRL水平已恢复正常。副作用轻微且短暂。CV 205 - 502似乎是治疗高泌乳素血症患者的一种有价值的化合物。
